BioScience Trends. 2024;18(1):42-48. (DOI: 10.5582/bst.2023.01326)

Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics

Wu JY, Wu JY, Li SQ, Luo MC, Zeng ZX, Li YN, Fu YK, Li H, Liu DY, Ou XY, Lin ZT, Wei SM, Yan ML


Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first-line standard-of-care treatments for uHCC are systematic therapies. However, treatments that combine locoregional therapy with systemic therapy are widely accepted in China and have demonstrated high rates of tumor response and conversion to resection with manageable toxicity. A literature review was performed by searching published literature in PubMed and Web of Science up to December 2023 for relevant articles on the use of triple therapy (transarterial chemoembolization combined with lenvatinib and anti–PD-1 antibodies) in uHCC. This review concentrates on the efficacy and safety of triple therapy with Chinese characteristics in patients with uHCC and describes the outcome of conversion surgery, degree of pathological necrosis, and effect prediction. This article will contribute to a comprehensive understanding of the role of triple therapy with Chinese characteristics in patients with uHCC.

KEYWORDS: hepatocellular carcinoma (HCC), conversion therapy, transcatheter arterial chemoembolization, lenvatinib, programmed death-1

Full Text: